1450 ET - CVS Health faces strong pushback from patients on its pharmacy-benefit manager's move to favor the weight-loss medication Wegovy over its rival Zepbound starting next month, UBS analysts say in a research note. Their checks of social media channels showed very high patient awareness of the upcoming changes, which would automatically give prior authorizations for Wegovy to anyone with a prior authorization for Zepbound. Appeals of this change can be made, but pricing remains unknown for successful appeals, the analysts say. Patient pushback is high; some have started a petition and have been contacting the government and employer HR departments to maintain Zepbound access, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
June 10, 2025 14:50 ET (18:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.